Farnesyltransferase inhibitors (FTIs) are among the first 'designer drugs' in clinical trials aimed at blocking cancer cell signal transduction. FTIs were made to attack tumors containing oncogenic Ras, whose function depends upon posttranslational farnesylation. Preclinical trials have demonstrated strikingly specific effects of FTIs against malignantly transformed cells. However, mechanistic investigations have raised doubts that Ras is a necessary target for drug inhibition. Thus, the mechanism of action and identity of FTI target proteins other than Ras have emerged as important questions. Guiding Hypothesis and Specific Aims. We propose to test the hypothesis that FTIs act in part through alteration of Rho prenylation and function (the 'FTI-Rho hypothesis'). Preliminary studies prompt RhoB as a paradigm for study. Cell adhesion and gene activation events related to FTI response and Rho alteration will be investigated. Mechanisms that distinguish apoptosis and cell growth inhibition by FTIs will be defined. In short, we aim to 1) establish Rho as an FTI target, 2) identify Rho-dependent events required to mediate FTI response, and 3) define the factors that dictate growth inhibition versus apoptosis. Innovation and Significance. The main element of innovation in our proposal is the shift of intellectual focus from Ras to Rho as a realm to understand the mechanism of FTI action in cancer cells. Defining FTI mechanism(s) will promote clinical applications as well as novel insights into cancer cell pathophysiology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082222-02
Application #
6173589
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Spalholz, Barbara A
Project Start
1999-09-30
Project End
2004-07-31
Budget Start
2000-08-09
Budget End
2001-07-31
Support Year
2
Fiscal Year
2000
Total Cost
$170,164
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Laury-Kleintop, Lisa D; Mulgrew, Jennifer R; Heletz, Ido et al. (2015) Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy. J Cell Biochem 116:2541-51
Kazerounian, Shiva; Gerald, Damien; Huang, Minzhou et al. (2013) RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res 73:50-61
Huang, Minzhou; Satchell, Lauren; Duhadaway, James B et al. (2011) RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem 112:1572-84
Muller, Alexander J; Mandik-Nayak, Laura; Prendergast, George C (2010) Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2:293-7
Muller, Alexander J; DuHadaway, James B; Chang, Mee Young et al. (2010) Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 59:1655-63
Muller, Alexander J; DuHadaway, James B; Jaller, Daniel et al. (2010) Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 70:1845-53
Scott, Grant N; DuHadaway, James; Pigott, Elizabeth et al. (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182:7509-17
Kumar, Sanjeev; Malachowski, William P; DuHadaway, James B et al. (2008) Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 51:1706-18
Kumar, Sanjeev; Jaller, Daniel; Patel, Bhumika et al. (2008) Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 51:4968-77
Muller, Alexander J; Sharma, Madhav D; Chandler, Phillip R et al. (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 105:17073-8

Showing the most recent 10 out of 31 publications